{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:23:38Z","timestamp":1792686218539,"version":"4.5.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aims to determine local treatment response and long-term survival outcomes in patients with localised muscle-invasive bladder cancer (MIBC) patients receiving neoadjuvant chemotherapy (NAC) using diffusion-weighted MRI (DWI) and apparent diffusion coefficient (ADC) analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with T2-T4aN0-3M0 bladder cancer suitable for NAC were recruited prospectively. DWI was performed prior to NAC and was repeated following NAC completion. Conventional response assessment was performed with cystoscopy and tumour site biopsy. Response was dichotomised into response (&amp;lt;T2) or poor response (\u2265T2). Patients proceeded to either radical cystectomy or chemo-radiotherapy as standard of care. Tumour ADC values were calculated for all b-values (ADC<jats:sub>all<\/jats:sub>) and high b-values (ADC<jats:sub>b100<\/jats:sub>). Mean ADC, percentiles, skew, kurtosis, and their change (\u0394ADC and %\u0394ADC) were determined. Threshold predictive of response with highest specificity was ascertained using receiver operating characteristic (ROC) analysis. Median overall survival (OS), bladder-cancer-specific survival (bCSS), progression-free survival (PFS), and time to cystectomy were estimated using Kaplan\u2013Meier method. Significant area under the curve (AUC) cut points were used to determine relationship with long-term endpoints and were compared using log-rank test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty-eight patients (96 DWI) were evaluated. NAC response was associated with significant increase in mean \u0394ADC and %\u0394ADC compared to poor response (\u0394ADC<jats:sub>all<\/jats:sub> 0.32\u00d710<jats:sup>\u22123<\/jats:sup> versus 0.11\u00d710<jats:sup>\u22123<\/jats:sup> mm<jats:sup>2<\/jats:sup>\/s; p=0.009, and %\u0394ADC<jats:sub>all<\/jats:sub> 21.70% versus 8.23%; p=0.013). Highest specificity predicting response was seen at 75th percentile ADC (AUC, 0.8; p=0.01). Sensitivity, specificity, positive predictive power, and negative predictive power of %\u0394ADC<jats:sub>b100<\/jats:sub> 75th percentile was 73.7%, 90.0%, 96.6%, and 52.9%, respectively. %\u0394ADC<jats:sub>b100<\/jats:sub> 75th percentile &amp;gt;15.5% was associated with significant improvement in OS (HR, 0.40; 95% CI, 0.19\u20130.86; p=0.0179), bCSS (HR, 0.26; 95% CI, 0.08\u20130.82; p=0.0214), PFS (HR, 0.16; 95% CI, 0.05\u20130.48; p=0.0012), and time to cystectomy (HR, 0.19; 95% CI, 0.07\u20130.47; p=0.0004).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Quantitative ADC analysis can successfully identify NAC response and improved long-term clinical outcomes. Multi-centre validation to assess reproducibility and repeatability is required before testing within clinical trials to inform MIBC treatment decision making.<\/jats:p><\/jats:sec><jats:sec><jats:title>Advances in knowledge<\/jats:title><jats:p>We successfully demonstrated that measured change in DWI can successfully identify NAC response and improved long-term survival outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.961393","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T05:31:16Z","timestamp":1668403876000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Diffusion-weighted MRI to determine response and long-term clinical outcomes in muscle-invasive bladder cancer following neoadjuvant chemotherapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Shaista","family":"Hafeez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir El","family":"Ghzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"D\u2019Arcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Lalondrelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Scurr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aslam","family":"Sohaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Anthony","family":"Huddart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J Clin Oncol"},{"key":"B4","unstructured":"Bladder cancer: diagnosis and management2015"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.10.016","article-title":"Predicting response to neoadjuvant chemotherapy in bladder cancer","volume":"6","author":"Motterle","year":"2020","journal-title":"Eur Urol Focus"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.162","article-title":"Imaging biomarker roadmap for cancer studies","volume":"14","author":"O\u2019Connor","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14366","article-title":"Diagnostic accuracy of magnetic resonance imaging for tumour staging of bladder cancer: systematic review and meta-analysis","volume":"122","author":"Gandhi","year":"2018","journal-title":"BJU Int"},{"key":"B11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejrad.2017.07.021","article-title":"Diagnostic performance of MRI for prediction of muscle-invasiveness of bladder cancer: A systematic review and meta-analysis","volume":"95","author":"Woo","year":"2017","journal-title":"Eur J Radiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2017171028","article-title":"The diagnostic value of MR imaging in differentiating T staging of bladder cancer: A meta-analysis","volume":"286","author":"Huang","year":"2018","journal-title":"Radiology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2009.08.024","article-title":"An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer","volume":"57","author":"Kulkarni","year":"2010","journal-title":"Eur Urol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.eururo.2018.06.024","article-title":"Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: New insights and updated recommendations","volume":"74","author":"Klaassen","year":"2018","journal-title":"Eur Urol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.01.001","article-title":"Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base","volume":"88","author":"Gray","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67522-2","article-title":"Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy","volume":"163","author":"Paik","year":"2000","journal-title":"J Urol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","article-title":"Multiparametric magnetic resonance imaging for bladder cancer: Development of VI-RADS (Vesical imaging-reporting and data system)","volume":"74","author":"Panebianco","year":"2018","journal-title":"Eur Urol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.11.065","article-title":"Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer","volume":"83","author":"Yoshida","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.24148","article-title":"Apparent diffusion coefficient value reflects invasive and proliferative potential of bladder cancer","volume":"39","author":"Kobayashi","year":"2014","journal-title":"J Magn Reson Imaging"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2014.04.019","article-title":"Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness","volume":"32","author":"Sevcenco","year":"2014","journal-title":"Urol Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-011-2174-7","article-title":"Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness","volume":"21","author":"Kobayashi","year":"2011","journal-title":"Eur Radiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2511080873","article-title":"Urinary bladder cancer: diffusion-weighted MR imaging\u2013accuracy for diagnosing T stage and estimating histologic grade","volume":"251","author":"Takeuchi","year":"2009","journal-title":"Radiology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1741-7015-11-104","article-title":"Advances in bladder cancer imaging","volume":"11","author":"Hafeez","year":"2013","journal-title":"BMC Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.06.111","article-title":"Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer","volume":"75","author":"Yoshida","year":"2010","journal-title":"Urology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.11110577","article-title":"Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging\u2013value of histogram analysis of apparent diffusion coefficients","volume":"261","author":"Kyriazi","year":"2011","journal-title":"Radiology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1148\/radiol.2483071407","article-title":"Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases","volume":"248","author":"Cui","year":"2008","journal-title":"Radiology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.07.048","article-title":"Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer","volume":"111","author":"Harry","year":"2008","journal-title":"Gynecol Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1593\/neo.81328","article-title":"Diffusion-weighted magnetic resonance imaging as a cancer biomarker: Consensus and recommendations","volume":"11","author":"Padhani","year":"2009","journal-title":"Neoplasia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-021-02963-7","article-title":"Diagnostic performance of contrast-enhanced dynamic and diffusion-weighted MR imaging in the assessment of tumor response to neoadjuvant therapy in muscle-invasive bladder cancer","volume":"46","author":"Ahmed","year":"2021","journal-title":"Abdominal Radiol (New York)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.109","article-title":"Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder","volume":"112","author":"Hafeez","year":"2015","journal-title":"Br J Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2007.05.007","article-title":"The value of hyoscine butylbromide in pelvic MRI","volume":"62","author":"Johnson","year":"2007","journal-title":"Clin Radiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11030237","article-title":"Liquid biopsy biomarkers in urine: A route towards molecular diagnosis and personalized medicine of bladder cancer","volume":"11","author":"Ferro","year":"2021","journal-title":"J Pers Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2017.03.08","article-title":"Liquid biopsies for bladder cancer","volume":"6","author":"Ward","year":"2017","journal-title":"Transl Androl Urol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","article-title":"Genomic alterations in liquid biopsies from patients with bladder cancer","volume":"70","author":"Birkenkamp-Demtroder","year":"2016","journal-title":"Eur Urol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1140","article-title":"Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer","volume":"23","author":"Vandekerkhove","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx405","article-title":"Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance","volume":"28","author":"Barata","year":"2017","journal-title":"Ann Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.08.004","article-title":"Circulating tumor cell and circulating tumor DNA assays reveal complementary information for patients with metastatic urothelial cancer","volume":"4","author":"Chalfin","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2022.03.005","article-title":"Highly sensitive and specific detection of bladder cancer via targeted ultra-deep sequencing of urinary DNA","author":"Ward","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14808","article-title":"Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification","volume":"124","author":"Ward","year":"2019","journal-title":"BJU Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.07.016.7","article-title":"Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"79","author":"Becker","year":"2021","journal-title":"Eur Urol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00505-w","article-title":"Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US food and drug administration and bladder cancer advocacy network workshop","volume":"19","author":"Chang","year":"2022","journal-title":"Nat Rev Urol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"17562872211039583","DOI":"10.1177\/17562872211039583","article-title":"Multiparametric magnetic resonance imaging for bladder cancer: a comprehensive systematic review of the vesical imaging-reporting and data system (VI-RADS) performance and potential clinical applications","volume":"13","author":"Seguier","year":"2021","journal-title":"Ther Adv Urol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.12.016","article-title":"Multiparametric magnetic resonance imaging as a noninvasive assessment of tumor response to neoadjuvant pembrolizumab in muscle-invasive bladder cancer: Preliminary findings from the PURE-01 study","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.4329\/wjr.v6.i6.344","article-title":"Diffusion-weighted magnetic resonance imaging in management of bladder cancer, particularly with multimodal bladder-sparing strategy","volume":"6","author":"Yoshida","year":"2014","journal-title":"World J Radiol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.34.2_suppl.403","article-title":"Evaluation of early response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using dynamic contrast-enhanced MRI and diffusion weighted MRI: MARBLE study","volume":"34","author":"Pearson","year":"2016","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.eururo.2006.01.022","article-title":"Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer","volume":"49","author":"Schrier","year":"2006","journal-title":"Eur Urol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-009-1543-y","article-title":"Apparent diffusion coefficient and vascular signal fraction measurements with magnetic resonance imaging: feasibility in metastatic ovarian cancer at 3 Tesla: technical development","volume":"20","author":"Sala","year":"2010","journal-title":"Eur Radiol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-014-3573-3","article-title":"Modelling DW-MRI data from primary and metastatic ovarian tumours","volume":"25","author":"Winfield","year":"2015","journal-title":"Eur Radiol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.24649","article-title":"Improved intravoxel incoherent motion analysis of diffusion weighted imaging by data driven Bayesian modeling","volume":"71","author":"Orton","year":"2014","journal-title":"Magn Reson Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.25196","article-title":"Diffusion-weighted imaging outside the brain: Consensus statement from an ISMRM-sponsored workshop","volume":"44","author":"Taouli","year":"2016","journal-title":"J Magn Reson Imaging"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1038\/ncomms5006","article-title":"Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach","volume":"5","author":"Aerts","year":"2014","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.25669","article-title":"Radiomics assessment of bladder cancer grade using texture features from diffusion-weighted imaging","volume":"46","author":"Zhang","year":"2017","journal-title":"J Magn Reson Imaging"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.990176","article-title":"The role of radiomics with machine learning in the prediction of muscle-invasive bladder cancer: A mini review","volume":"12","author":"Huang","year":"2022","journal-title":"Front Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.619893","article-title":"Combining multiparametric MRI radiomics signature with the vesical imaging-reporting and data system (VI-RADS) score to preoperatively differentiate muscle invasion of bladder cancer","volume":"11","author":"Zheng","year":"2021","journal-title":"Front Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.02.021","article-title":"Comparing an imaging-guided pathway with the standard pathway for staging muscle-invasive bladder cancer: Preliminary data from the BladderPath study","volume":"80","author":"Bryan","year":"2021","journal-title":"Eur Urol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.961393\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T05:31:20Z","timestamp":1668403880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.961393\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":56,"alternative-id":["10.3389\/fonc.2022.961393"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.961393","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,14]]},"article-number":"961393"}}